Ambu A/S (OTCMKTS:AMBBY) Shares Gap Up - Should You Buy?

Key Points

• Shares of Ambu A/S gapped up from a previous close of $14.75 to open at $15.42, with a trading volume of 701 shares.
• UBS Group upgraded Ambu A/S to a "strong-buy" rating, contributing to the company's overall consensus rating of "Strong Buy".
• For the last quarterly earnings, Ambu A/S reported earnings per share of $0.07, with a revenue of $229.16 million and a net margin of 5.93%.

Shares of Ambu A/S Unsponsored ADR (OTCMKTS:AMBBY - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $14.75, but opened at $15.42. Ambu A/S shares last traded at $15.42, with a volume of 701 shares changing hands.

Analyst Ratings Changes

Separately, UBS Group upgraded shares of Ambu A/S to a "strong-buy" rating in a research report on Tuesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, Ambu A/S presently has a consensus rating of "Strong Buy".

Ambu A/S Stock Up 4.5%

The business's 50 day moving average is $15.08 and its 200 day moving average is $16.03. The company has a market capitalization of $3.62 billion, a price-to-earnings ratio of 81.16 and a beta of 0.88. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.67 and a current ratio of 2.88.

Ambu A/S (OTCMKTS:AMBBY - Get Free Report) last posted its quarterly earnings results on Friday, August 22nd. The company reported $0.07 earnings per share (EPS) for the quarter. Ambu A/S had a net margin of 5.93% and a return on equity of 6.24%. The company had revenue of $229.16 million during the quarter.

About Ambu A/S

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.